Literature DB >> 8186324

The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils.

J K Jenkins1, M Malyak, W P Arend.   

Abstract

LPS stimulates human monocytes and neutrophils to produce IL-1 beta and IL-1 receptor antagonist (IL-1ra). IL-10 has been shown to inhibit LPS-induced IL-1 beta production in human monocytes. The objective of these studies was to examine the effects of IL-10 on human monocyte and neutrophil IL-1ra protein and mRNA production and compare it to IL-1 beta. IL-10 markedly inhibited LPS-induced IL-1 beta mRNA and protein production in both cell types. IL-10 alone induced IL-1ra mRNA production in monocytes with a low level of protein production. Furthermore, IL-10 led to enhanced levels of IL-1ra mRNA in LPS-induced monocytes at 2 to 6 h and of IL-1ra protein at 4-16 h, but there was no increase in levels of IL-1ra protein at 24 h or later. In neutrophils IL-10 alone did not stimulate IL-1ra protein or mRNA production and did not augment LPS-induced IL-1ra mRNA. These net effects of IL-10 resulted in an increase in the ratio of IL-1ra to IL-1 beta in both neutrophils and monocytes. The net effects of IL-10 on inflammatory cells may be important in modulation of biologic responses to IL-1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186324

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  37 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

Authors:  Andrew D Vonberg; Maria Acevedo-Calado; Aaron R Cox; Susan L Pietropaolo; Roberto Gianani; Steven K Lundy; Massimo Pietropaolo
Journal:  JCI Insight       Date:  2018-12-06

Review 3.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

Review 4.  Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.

Authors:  Kristina Ludigs; Valeriy Parfenov; Renaud A Du Pasquier; Greta Guarda
Journal:  Cell Mol Life Sci       Date:  2012-04-24       Impact factor: 9.261

5.  [Intra-articular therapy with autologous interleukin-1 receptor antagonist in osteoarthritis. Innovation or quackery?].

Authors:  D Stengel; A Ekkernkamp; M Wich
Journal:  Unfallchirurg       Date:  2004-11       Impact factor: 1.000

6.  Immunotoxic effects of exposure of rats to xenobiotics via maternal lactation. Part I 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  J S Badesha; G Maliji; B Flaks
Journal:  Int J Exp Pathol       Date:  1995-12       Impact factor: 1.925

Review 7.  The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?

Authors:  Muki S Shey; Nigel J Garrett; Lyle R McKinnon; Jo-Ann S Passmore
Journal:  Innate Immun       Date:  2013-11-26       Impact factor: 2.680

8.  MicroRNA-9 promotion of interleukin-6 expression by inhibiting monocyte chemoattractant protein-induced protein 1 expression in interleukin-1β-stimulated human chondrocytes.

Authors:  Mohammad S Makki; Abdul Haseeb; Tariq M Haqqi
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

9.  Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.

Authors:  D J Berg; R Kühn; K Rajewsky; W Müller; S Menon; N Davidson; G Grünig; D Rennick
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide.

Authors:  S M Levitz; A Tabuni; S H Nong; D T Golenbock
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.